A 38-year-old man with schizophrenia has been on risperidone 6 mg/day for 8 months. He presents to the psychiatry clinic with complaints of bilateral breast enlargement and galactorrhea for the past 2 months. Serum prolactin is 85 ng/mL (normal <25 ng/mL). He is otherwise clinically stable on his current antipsychotic regimen. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis The patient presents with **hyperprolactinemia-induced gynecomastia and galactorrhea** secondary to risperidone, a potent D₂ dopamine receptor antagonist. His prolactin level (85 ng/mL) is significantly elevated, and the temporal relationship to antipsychotic initiation is clear. ## Management Approach for Antipsychotic-Induced Hyperprolactinemia **Key Point:** When an antipsychotic causes clinically significant hyperprolactinemia with bothersome symptoms, switching to a prolactin-sparing agent is the preferred first-line strategy, provided the patient's psychotic symptoms remain controlled. ### Why Switch Rather Than Add or Reduce? | Strategy | Rationale | Outcome | |----------|-----------|----------| | **Switch to prolactin-sparing agent** | Aripiprazole, quetiapine, clozapine have minimal D₂ antagonism; maintain antipsychotic efficacy | Prolactin normalizes; symptoms resolve | | Reduce dose | Risk of psychotic relapse; may not fully normalize prolactin | Suboptimal | | Add dopamine agonist | Adds medication burden; drug interactions; not first-line | Reserved for cases where switch is contraindicated | | MRI pituitary | Unnecessary if clinical picture fits antipsychotic-induced hyperprolactinemia | Delays appropriate management | **High-Yield:** Aripiprazole is the preferred switch agent because it is a **partial D₂ agonist**, which actually *lowers* prolactin levels compared to baseline in many patients, while maintaining antipsychotic efficacy. ### Clinical Pearl The patient is clinically stable on risperidone (8 months without relapse), making a switch to an equally or more efficacious prolactin-sparing agent safe and appropriate. Gynecomastia and galactorrhea are bothersome, socially stigmatizing symptoms that warrant intervention. ## Why Other Options Are Suboptimal - **Bromocriptine addition:** Adds polypharmacy; dopamine agonists can theoretically worsen psychosis; not first-line for antipsychotic-induced hyperprolactinemia when switching is feasible. - **Dose reduction:** Risks psychotic decompensation and may not fully resolve prolactin elevation. - **MRI pituitary:** Unnecessary in this context. Prolactinoma is rare (1:1000 population); the clinical picture is diagnostic of antipsychotic-induced hyperprolactinemia. MRI is indicated only if prolactin >200 ng/mL, visual symptoms, or failure to normalize after drug change. [cite:Stahl's Essential Psychopharmacology Ch 5]